Search results
Results from the WOW.Com Content Network
During the COVID-19 pandemic, several COVID-19 vaccines were developed, and in December 2020 the first vaccination campaign was planned. Anticipating the vaccine, on 23 November 2020, Qantas announced that the company would ask for proof of COVID-19 vaccination from international travellers. According to Alan Joyce, the firm's CEO, a ...
The COVID-19 pandemic in Kenya was a part of the worldwide pandemic of coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus was confirmed to have reached Kenya on 12 March 2020, [3] with the initial cases reported in the capital city Nairobi and in the coastal area Mombasa .
Share of people who received at least one dose of COVID-19 vaccine in the world. COVID-19 vaccination programs are ongoing in the majority countries and territories in Africa, with 51 of 54 African countries having launched vaccination programs by July 2021. [1] As of October 2023, 51.8% of the continent's population is fully vaccinated with ...
April 11, 2024 at 1:09 PM. (Reuters) -Moderna said on Thursday it had paused its plans to build a vaccine manufacturing facility in Kenya, following a post-pandemic decline in demand for COVID-19 ...
An International Certificate of Vaccination or Revaccination Against Yellow Fever, issued in the Soviet Union in 1985. The International Certificate of Inoculation and Vaccination was established by the International Sanitary Convention for Aerial Navigation (1933) in The Hague, which came into force on 1 August 1935 and was amended in 1944. [3]
The Sanofi–GSK COVID‑19 vaccine is a recombinant protein subunit vaccine containing the SARS-CoV-2 spike protein, which is produced in insect cells via a baculovirus vector. It also includes an adjuvant made by GSK. It uses the same technology as Sanofi's Flublok influenza vaccine. [7] [8]
The Oxford–AstraZeneca COVID-19 vaccine, sold under the brand names Vaxzevria[6]and Covishield,[7]is a viral vector vaccine[8]produced by the British University of Oxford, British-Swedish company AstraZeneca, and the Coalition for Epidemic Preparedness Innovations. [8][9][10]Finland, Denmark, and Norway suspended the use of the Oxford ...
COVID-19 Vaccines Global Access (COVAX) is one of its four pillars. It is a worldwide initiative aimed at equitable access to COVID-19 vaccines directed by the GAVI vaccine alliance, the Coalition for Epidemic Preparedness Innovations (CEPI), and the WHO, alongside key delivery partner UNICEF.